There are currently no recommendations for anyone to be vaccinated against bird flu and federal health officials note this is ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...

Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as ...

Attorney General Bridget Hill announced a settlement with Sanofi-Aventis U.S. LLC (Sanofi), which guarantees that Wyoming ...

Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...

GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a ...

Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

Sanofi (SNY) sells global rights to Enjaymo treatment for cold agglutinin disease to Recordati (RCDTF) in a deal worth up to ...

Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...

On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...